Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
about
Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging rolesAnnotating STEAP1 regulation in prostate cancer with 89Zr immuno-PETAlternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitorsApplying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.Imaging active urokinase plasminogen activator in prostate cancer.Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.Imaging tumor burden in the brain with 89Zr-transferrinp-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPETTranslational Molecular Imaging of Prostate Cancer.Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab(89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges.Strategies for imaging androgen receptor signaling pathway in prostate cancer: implications for hormonal manipulation and radiation treatment.Near-infrared fluorescence and nuclear imaging and targeting of prostate cancer.Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.New prospects for PET in prostate cancer imaging: a physicist's viewpoint.Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies.NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic.The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodiesStatus and trends in the development of clinical diagnostic agents.Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer.Measuring glucocorticoid receptor expression in vivo with PET.
P2860
Q26865810-7E2BEB0D-C099-4FA2-AD3C-59F384AEE643Q30643770-FB671C2C-05BF-4829-99D6-6791E76748B4Q33761754-AC4B3FF3-A9CF-4297-8511-E84E46530DD7Q34119201-ADD91AA9-0B9D-4B2F-88BC-1BD5A541A060Q34717742-35B0CD07-4256-4E06-8CA5-059479EBF68CQ34732727-5507ACF8-1A73-43E4-933C-C261D02F8F21Q34762185-A201345E-ACAE-4391-81F9-5C271BF8ECE2Q35251858-301AE45D-CA41-4B4C-947B-172901D2B00AQ35675446-575BFAC2-E09A-4395-8580-50ED5DE31EC2Q35755818-37A00F87-E6A3-401E-8C54-123595C9A313Q36429530-B26872F9-0393-4CBD-8D94-434828736CCFQ36849160-F994A002-1423-44A6-AB22-5046A90FA730Q37106244-EDBAACC9-AC87-4EFD-A21A-9C795516129CQ37129847-D59FCBA6-FC94-47AE-A09E-1259718AE972Q37244969-C28D4B97-2B92-402B-8B1F-C507A30CE12EQ37708758-FC974C68-1080-4F4F-B258-7DB94EB7CEABQ38111973-02936CA8-1E6B-4BB8-A37A-E7F6A654847EQ38167022-8410CE90-18C5-4DE6-8F78-395E926B326EQ38256977-A5635B03-9695-44E6-9E3A-3CAE7A7B7C8DQ38360681-6BF28B55-30B7-40FB-A039-24209FC6136CQ38616392-3BF170A5-ACBB-4CF0-ACA2-7AF924AA639BQ38760061-A51B9D86-02F3-4E7D-AB4D-8FB29F1F230BQ38767020-D6BB8115-36F7-4D50-B39E-69431B061186Q38865487-6C1E0C84-A9AE-4FEF-966F-1D36F418943DQ38903311-EB1F2208-A68F-4DF1-9D30-1A55FAE8F364Q38995734-82BB5E51-E8D6-4F92-84F2-1FDA765652CDQ39254330-54BF47FE-07C5-4263-A43F-9B8623CD2F73Q41495773-F30D97AF-5474-463E-946D-31FD359FBD9BQ52565489-47140636-BC7B-48A3-8A32-C698D1AB71E2Q55248523-4D88EBFF-D73F-4E50-904C-DA0333DCDD3A
P2860
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Imaging androgen receptor sign ...... ree prostate-specific antigen.
@ast
Imaging androgen receptor sign ...... ree prostate-specific antigen.
@en
type
label
Imaging androgen receptor sign ...... ree prostate-specific antigen.
@ast
Imaging androgen receptor sign ...... ree prostate-specific antigen.
@en
prefLabel
Imaging androgen receptor sign ...... ree prostate-specific antigen.
@ast
Imaging androgen receptor sign ...... ree prostate-specific antigen.
@en
P2093
P2860
P50
P1433
P1476
Imaging androgen receptor sign ...... free prostate-specific antigen
@en
P2093
Charles L Sawyers
John Wongvipat
Kim Pettersson
Michael J Evans
Per-Anders Abrahamsson
Peter T Scardino
Steven M Larson
P2860
P304
P356
10.1158/2159-8290.CD-11-0316
P577
2012-03-31T00:00:00Z